NCT05600309 2025-11-26A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyMerck Sharp & Dohme LLCPhase 3 Completed94 enrolled 15 charts